A fresh 30-mL of urine sample will be collected either by way of clean catch or Foley catheter tubing will be collected at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs). 10cc of blood will be collected from the peripheral vessel once at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs).

Gastrointestinal Hemorrhage

Liver Cirrhosis

Acute Kidney Injury

Taipei Veterans General Hospital, Taiwan

Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage

Optimal Clinical Predictors to Acute Kidney Injury in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage

Incidence rates of AKI in patient suffering from acute gastrointestinal hemorrhage

vghtpe user

Taipei Veterans General Hospital

Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.

Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.

Inflammation

Veins

Complication

Varicose Veins

Varicose Ulcer

Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.

Peripheral blood draw

CIFL- Interuniversity Center of Phlebolymphology

The Role of Pyroptosis in Chronic Venous Disease

The Role of Pyroptosis in Chronic Venous Disease and Its Pathophysiological Implication

Caspase-1 evaluation to be presented in pg/ml

IL-1 β, IL-4, IL-10, IL-18, and TNF-α evaluation to presented in pg/ml

Prof. Raffaele Serra, MD, Ph.D.

Clinical Professor

University of Catanzaro

Hepatitis C

Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel

Real World Experience of Chronic Hepatitis C Treatment in Israeli Patients With Advanced Liver Fibrosis With Fixed Dose Combination (FDC) Grazoprevir (100 mg)/Elbasvir (50mg) (Zepatier) ± Ribavirin: A Retrospective Multicenter Cohort Study

SVR12 is defined as hepatitis c virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification 12 weeks after the last dose of treatment

Adverse event from the time when the decision is made to initiate treatment with Elbasvir/Grazoprevir until after the last dose

Eli Zuckerman

Prof. Eli Zuckerman

Carmel Medical Center

Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)

Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)

Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)
Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks
Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)
Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks
Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks

Chronic Hepatitis C

Cirrhosis

Pegylated interferon alfa-2a + Ribavirin

Pegylated interferon alfa-2a + Ribavirin + Boceprevir

Pegylated interferon alfa-2a + Ribavirin +Telaprevir

Ledipasvir/Sofosbuvir

Ombitasvir/paritaprevir/ritonavir+Dasabuvir

Daclatasvir+Sofosbuvir

Simeprevir+Sofosbuvir

Impact of Antiviral Therapy on Gastroesophageal Varices.

Efficacy and Safety of Interferon Based Therapy and Interferon-free Direct-acting Antivirals in Cirrhotic Patients With Hepatitis C. Impact of Antiviral Therapy on Gastroesophageal Varices.

undetectable HCV viral load 12 weeks after the end of antiviral treatment in each cohort of antiviral treatment

Number of patients with GOV before and 12-24 weeks after treatment completion in patients with or without SVR

varicose veins/protease

Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage

The Role of Pyroptosis in Chronic Venous Disease

Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel

Impact of Antiviral Therapy on Gastroesophageal Varices.

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus